| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
14,078 |
4,754 |
$1.55M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
10,989 |
9,624 |
$1.12M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
8,910 |
7,458 |
$515K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
4,218 |
4,082 |
$396K |
| 95910 |
|
1,910 |
1,060 |
$203K |
| 64721 |
|
206 |
204 |
$126K |
| 95908 |
|
1,251 |
681 |
$121K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
4,839 |
4,052 |
$80K |
| 95886 |
|
5,327 |
2,410 |
$70K |
| 01810 |
|
1,548 |
1,521 |
$57K |
| 01830 |
|
1,188 |
1,180 |
$47K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,435 |
2,316 |
$40K |
| 76000 |
|
1,566 |
1,260 |
$38K |
| 64417 |
|
1,320 |
1,286 |
$33K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,859 |
2,767 |
$29K |
| 80061 |
Lipid panel |
3,330 |
3,131 |
$27K |
| 80053 |
Comprehensive metabolic panel |
4,256 |
4,128 |
$25K |
| 73222 |
|
110 |
57 |
$24K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,455 |
1,157 |
$22K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
1,717 |
1,696 |
$20K |
| 95909 |
|
201 |
109 |
$19K |
| 26445 |
|
24 |
14 |
$18K |
| 86803 |
|
2,158 |
2,110 |
$16K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
181 |
93 |
$16K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,480 |
2,392 |
$14K |
| 85027 |
|
3,493 |
3,449 |
$12K |
| 64415 |
|
326 |
313 |
$12K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
173 |
141 |
$11K |
| 87340 |
|
2,038 |
2,006 |
$11K |
| 86780 |
|
1,572 |
1,553 |
$10K |
| 73115 |
|
92 |
50 |
$10K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
404 |
398 |
$9K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
403 |
397 |
$9K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
400 |
393 |
$8K |
| 84439 |
|
1,489 |
1,450 |
$8K |
| 84481 |
|
684 |
677 |
$7K |
| 82607 |
|
803 |
801 |
$6K |
| 86706 |
|
1,121 |
1,067 |
$6K |
| 86704 |
|
968 |
924 |
$6K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,214 |
1,122 |
$6K |
| 84153 |
|
481 |
475 |
$5K |
| 86790 |
|
652 |
612 |
$5K |
| 86705 |
|
748 |
741 |
$4K |
| 80074 |
|
175 |
145 |
$4K |
| 87481 |
|
191 |
188 |
$4K |
| 87563 |
|
198 |
196 |
$4K |
| 87511 |
|
185 |
184 |
$4K |
| 73221 |
|
46 |
24 |
$3K |
| 82746 |
|
357 |
356 |
$3K |
| 87653 |
|
159 |
158 |
$3K |
| 82728 |
|
376 |
375 |
$3K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
210 |
186 |
$3K |
| 76942 |
|
1,905 |
1,858 |
$3K |
| 20680 |
|
26 |
25 |
$3K |
| 0001A |
|
71 |
70 |
$2K |
| 0002A |
|
65 |
64 |
$2K |
| 73218 |
|
24 |
13 |
$2K |
| 87529 |
|
86 |
86 |
$2K |
| 83550 |
|
347 |
347 |
$2K |
| 25246 |
|
87 |
49 |
$2K |
| 86696 |
|
168 |
167 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
2,105 |
2,028 |
$2K |
| 83540 |
|
356 |
355 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
284 |
282 |
$1K |
| 86695 |
|
168 |
167 |
$1K |
| 73200 |
|
28 |
14 |
$1K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
50 |
37 |
$1K |
| 84550 |
|
382 |
382 |
$1K |
| 84460 |
|
416 |
409 |
$1K |
| 88304 |
|
76 |
71 |
$971.66 |
| 84450 |
|
416 |
409 |
$912.54 |
| 76376 |
|
267 |
153 |
$904.80 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
76 |
64 |
$869.80 |
| 84403 |
|
47 |
47 |
$763.77 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
25 |
25 |
$735.74 |
| 84238 |
|
28 |
28 |
$612.65 |
| 86328 |
|
46 |
45 |
$553.13 |
| 86709 |
|
93 |
84 |
$549.33 |
| 95885 |
|
67 |
44 |
$517.72 |
| 83615 |
|
176 |
176 |
$517.42 |
| 83721 |
|
81 |
81 |
$494.59 |
| 86702 |
|
66 |
62 |
$419.71 |
| 83718 |
|
90 |
90 |
$357.05 |
| 86592 |
|
145 |
140 |
$335.27 |
| 82550 |
|
74 |
74 |
$305.88 |
| 84478 |
|
90 |
90 |
$253.44 |
| 82465 |
|
114 |
114 |
$250.98 |
| 84402 |
|
13 |
13 |
$221.79 |
| 86038 |
|
28 |
28 |
$221.65 |
| 85652 |
|
91 |
91 |
$149.07 |
| 85045 |
|
53 |
53 |
$144.44 |
| 86140 |
|
35 |
35 |
$110.22 |
| 83735 |
|
25 |
25 |
$106.95 |
| 86431 |
|
27 |
27 |
$99.55 |
| 82947 |
|
34 |
34 |
$86.49 |
| 84100 |
|
25 |
25 |
$72.44 |
| 81001 |
|
38 |
38 |
$71.41 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12 |
12 |
$61.18 |
| 84520 |
|
26 |
26 |
$60.65 |
| 82565 |
|
14 |
14 |
$45.47 |
| 80050 |
General health panel |
244 |
171 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
157 |
155 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
42 |
42 |
$0.00 |